Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H₁ antagonists. Part I.

Furber M, Alcaraz L, Luckhurst C, Bahl A, Beaton H, Bowers K, Collington J, Denton R, Donald D, Kinchin E, MacDonald C, Rigby A, Riley R, Soars M, Springthorpe B, Webborn P.

Bioorg Med Chem Lett. 2012 Dec 15;22(24):7702-6. doi: 10.1016/j.bmcl.2012.09.113. Epub 2012 Oct 23.

PMID:
23142617
2.

Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H₁ antagonists. Part II: optimising in vivo clearance.

Furber M, Alcaraz L, Luckhurst C, Bahl A, Beaton H, Bowers K, Collington J, Denton R, Donald D, Kinchin E, MacDonald C, Rigby A, Riley R, Soars M, Springthorpe B, Webborn P.

Bioorg Med Chem Lett. 2012 Dec 15;22(24):7707-10. doi: 10.1016/j.bmcl.2012.09.112. Epub 2012 Oct 10.

PMID:
23116889
3.

The discovery of CCR3/H1 dual antagonists with reduced hERG risk.

Bahl A, Barton P, Bowers K, Brough S, Evans R, Luckhurst CA, Mochel T, Perry MW, Rigby A, Riley RJ, Sanganee H, Sisson A, Springthorpe B.

Bioorg Med Chem Lett. 2012 Nov 1;22(21):6688-93. doi: 10.1016/j.bmcl.2012.08.124. Epub 2012 Sep 15.

PMID:
23031591
4.

Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.

Bahl A, Barton P, Bowers K, Caffrey MV, Denton R, Gilmour P, Hawley S, Linannen T, Luckhurst CA, Mochel T, Perry MW, Riley RJ, Roe E, Springthorpe B, Stein L, Webborn P.

Bioorg Med Chem Lett. 2012 Nov 1;22(21):6694-9. doi: 10.1016/j.bmcl.2012.08.103. Epub 2012 Sep 11.

PMID:
23021991
5.

Overcoming undesirable HERG potency of chemokine receptor antagonists using baseline lipophilicity relationships.

Shamovsky I, Connolly S, David L, Ivanova S, Nordén B, Springthorpe B, Urbahns K.

J Med Chem. 2008 Mar 13;51(5):1162-78. doi: 10.1021/jm070543k. Epub 2008 Feb 8.

PMID:
18257512
6.

The influence of drug-like concepts on decision-making in medicinal chemistry.

Leeson PD, Springthorpe B.

Nat Rev Drug Discov. 2007 Nov;6(11):881-90. doi: 10.1038/nrd2445. Review.

PMID:
17971784
7.

From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis.

Springthorpe B, Bailey A, Barton P, Birkinshaw TN, Bonnert RV, Brown RC, Chapman D, Dixon J, Guile SD, Humphries RG, Hunt SF, Ince F, Ingall AH, Kirk IP, Leeson PD, Leff P, Lewis RJ, Martin BP, McGinnity DF, Mortimore MP, Paine SW, Pairaudeau G, Patel A, Rigby AJ, Riley RJ, Teobald BJ, Tomlinson W, Webborn PJ, Willis PA.

Bioorg Med Chem Lett. 2007 Nov 1;17(21):6013-8. Epub 2007 Aug 19.

PMID:
17827008
8.

Which hydroxy? Evidence for species differences in the regioselectivity of glucuronidation in rat, dog, and human in vitro systems and dog in vivo.

Martin IJ, Lewis RJ, Bernstein MA, Beattie IG, Martin CA, Riley RJ, Springthorpe B.

Drug Metab Dispos. 2006 Sep;34(9):1502-7. Epub 2006 Jun 8.

PMID:
16763016
9.

FPL 63012AR: a potent D1-receptor agonist.

Smith GW, Farmer JB, Ince F, Matu K, Mitchell PD, Naya I, Springthorpe B.

Br J Pharmacol. 1990 Jun;100(2):295-300.

10.

Paediatric emergencies: recognition, resuscitation and referral of the severely ill child.

Springthorpe B.

Aust Fam Physician. 1982 Jul;11(7):511, 513-5, 518-23. No abstract available.

PMID:
7138389
11.

Non-accidental childhood injury presenting at a hospital casualty department.

Springthorpe BJ, Oates RK, Hayes SC.

Med J Aust. 1977 Nov 5;2(19):629-32.

PMID:
607097
12.

Medical problems in refugee children evacuated from South Vietnam.

Hodson EM, Springthorpe BJ.

Med J Aust. 1976 Nov 13;2(20):747-9.

PMID:
1004330

Supplemental Content

Loading ...
Support Center